摘要呼吸道合胞病毒（RSV）是引起儿童呼吸道感染的重要病原之一，也是造成儿童住院及死亡的主要原因。但目前治疗措施以支持治疗为主，缺乏特异性抗病毒药物，预防RSV感染非常重要。主动、被动免疫为预防感染的主要方式，但由于单克隆抗体价格昂贵及部分需多剂注射 ...

【数据支撑】目前，Arexvy已获美国批准用于预防60岁及以上成年人中RSV相关疾病，同时也适用于50至59岁具有风险因素的成人。此次新申请主要针对年龄段在50岁以下但存在高风险因素的人群。美国FDA预计将在2026年上半年针对该申请做出决策，同时欧 ...

Abrysvo预防严重RSV下呼吸道疾病的有效率则约为86%。 mRESVIA预防严重RSV下呼吸道疾病的有效率约为83.7%。 MACD金叉信号形成，这些股涨势不错！

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

【8月13日，辉瑞披露关键性3期临床试验MONeT的子研究B相关结果】结果表明，在18岁及以上免疫功能低下的成年患者中，这些属于有发展为严重呼吸道 ...

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

ABRYSVO™ is approved by Health Canada for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older. i ABRYSVO™ is also the only RSV vaccine ...

Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025 ...